We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial (413720)

ARTG ID 413720

ARTG Name

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial

Product name

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial

ARTG Date

21 December 2023

Registration Type

Medicine

Therapeutic good type

Medicines

Ingredients

famtozinameran

tozinameran

Licence category

RE

Licence status

A

Summary

Related information

COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial (2024-25)

2024-25

Annual charge exemption

Exempt from annual charge in 2024-25 due to Pfizer Australia Pty Ltd declaring $0 turnover in that period.
COMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-19 VACCINE 5/5 micrograms/0.3 mL suspension for injection single dose vial, Pfizer Australia Pty Ltd, CON-1305

9 December 2024

Section 14 consent

Consent to import and supply while noncompliant with standards. The consent is effective from 9 December 2024 until 1 October 2026.